- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07663305
Evaluation of a Mobile Menopause Application (EMMA)
This study examines whether a digital app can help women manage symptoms of menopause. A total of 426 women with medically confirmed menopausal symptoms are randomly assigned to either use the app in addition to their usual medical care for 24 weeks, or to continue with usual care alone. The app provides evidence-based content and exercises for multimodal menopause management. Participants are followed up over 24 weeks, with the primary outcome assessed at 12 weeks. The main goal is to evaluate whether the app improves menopause-specific quality of life.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Hanover, Allemagne
- Recrutement
- Medicoles
-
Chercheur principal:
- Elisabeth Siegmund-Schultze, Dr. med.
-
Contact:
- Elisabeth Siegmund-Schultze, Dr. med.
- E-mail: studienleitung@wechseljahr-studie.de
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Legal capacity
- Ability to provide informed consent
- Residency in Germany
- Female gender
- Age ≥18 years
- Medically confirmed menopausal or other perimenopausal disorder (N95.1)
- Ownership of a smartphone and ability to use it
- Internet access for app usage and questionnaire completion
- Email address for registration
- Willingness to complete questionnaires online
- Motivation for regular app usage
- Sufficient proficiency in the German language
- MRS II ≥ 9
- Absence of exclusion criteria
Exclusion Criteria:
- Pregnancy or breastfeeding during the study period
- Current hormonal replacement therapy (HRT), initiation of HRT within eight weeks prior to study start and/or planned start of HRT during the study period
- Changes in treatment with psychotropic medication within eight weeks prior to study start and/or planned during the study period
- Start of psychotherapy within eight weeks prior to study start and/or planned during the study period
- Start of a rehabilitation program within eight weeks prior to study start and/or planned during the study period
- Surgery performed within eight weeks prior to study start and/or planned during the study period
- Previous or current access to the Endo-App or other comparable digital health applications, or current active prescription
- Current participation in other clinical studies
- Failure to meet the inclusion criteria
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Control Group
The control group has access to care-as-usual only. |
|
|
Expérimental: Intervention Group
The intervention group has access to the menopause app and its functions in addition to care-as-usual. |
The menopause app facilitates the implementation of multimodal self-management strategies in the daily routines of individuals with a menopausal disorder, through tools such as a symptom diary and guided interactive exercises. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Menopause-specific quality of life
Délai: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Menopause-specific Quality of Life Questionnaire (MENQOL) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Menopause-specific symptom severity
Délai: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Menopause Rating Scale (MRS II) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Daily interference due to hot flashes
Délai: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Hot Flash Related Daily Interference Scale (HFRDIS) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-specific impairment in daily activities
Délai: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Activity Impairment domain of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Patient activation
Délai: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the Patient Activation Measure 13 (PAM-13) |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Menopause-specific quality of life
Délai: Changes between time point T0 (baseline) and T4 (24 weeks after baseline)
|
Assessed with the Menopause-specific Quality of Life Questionnaire (MENQOL) |
Changes between time point T0 (baseline) and T4 (24 weeks after baseline)
|
|
Menopause-related absenteeism
Délai: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the absenteeism domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-related presenteeism
Délai: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the presenteeism domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
|
Menopause-related work productivity loss
Délai: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Assessed with the work productivity loss domain score of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause). |
Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- RCT_EMMA
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .